NATCO Pharma's Q3 PAT Rises 14% YoY, But QoQ Revenue Plummets 52%

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
NATCO Pharma's Q3 PAT Rises 14% YoY, But QoQ Revenue Plummets 52%
Overview

NATCO Pharma reported a mixed bag for Q3FY26. While consolidated revenue grew 8.34% YoY to ₹705.4 crore and PAT increased 14.27% YoY to ₹151.3 crore, the company saw a significant 51.79% sequential drop in revenue and a 70.80% fall in PAT from Q2FY26. This decline was attributed to a sharp drop in 'Formulations export' revenue. The acquisition of a stake in South Africa's Adcock Ingram is impacting financials with amortisation costs. Strategic moves include evaluating an Agro Chemicals business demerger and incorporating a new Chilean subsidiary.

NATCO Pharma Navigates Quarterly Volatility Amidst Strategic Acquisitions

NATCO Pharma Limited has announced its Q3FY26 financial results, presenting a picture of robust year-on-year (YoY) growth juxtaposed with a stark sequential (QoQ) downturn. Consolidated revenue for the quarter ended December 31, 2025, stood at ₹705.4 crore, marking an 8.34% increase from ₹651.1 crore in Q3FY25. However, this figure represents a significant 51.79% decline from the ₹1463.0 crore reported in the preceding quarter (Q2FY26). Consolidated Profit After Tax (PAT) mirrored this trend, rising 14.27% YoY to ₹151.3 crore, but falling a precipitous 70.80% QoQ from ₹517.9 crore in Q2FY26. The consolidated EBITDA margin was reported at a healthy 30.7% for Q3FY26.

On a standalone basis, the PAT saw a YoY decline of 14.41% to ₹106.9 crore in Q3FY26, and a substantial QoQ decrease of 78.72% from ₹500.9 crore in Q2FY26.

📉 The Financial Deep Dive

  • The Numbers: Consolidated Revenue grew 8.34% YoY to ₹705.4 crore, but plunged 51.79% QoQ from ₹1463.0 crore. Consolidated PAT climbed 14.27% YoY to ₹151.3 crore, yet dropped 70.80% QoQ from ₹517.9 crore. The consolidated EBITDA margin for Q3FY26 was 30.7%.
  • Segment Performance: The Pharmaceuticals segment revenue saw a strong YoY growth of 34.64% to ₹618.9 crore. Agro Chemicals (CHS) also reported a substantial YoY increase of 88.74% to ₹28.5 crore. The primary driver for the QoQ revenue decline appears to be the 'Formulations export' segment, which fell from ₹1147.0 crore in Q2FY26 to ₹421.4 crore in Q3FY26.
  • The Acquisition Impact: The financial results were influenced by the acquisition of a 35.75% stake in South Africa's Adcock Ingram Holdings Limited, completed in November 2025. This transaction led to a one-time amortisation of ₹18.75 crore, with the associate's profit contribution amounting to ₹10.90 crore in Q3FY26.
  • The Grill: Investors will be keen to understand the reasons behind the sharp QoQ revenue contraction, particularly from the 'Formulations export' segment, during the upcoming earnings call. The immediate financial impact and integration strategy for Adcock Ingram will also be key discussion points.

🚩 Risks & Outlook

  • Specific Risks: The significant QoQ revenue drop highlights potential seasonality, demand fluctuations in export markets, or execution challenges. The standalone PAT decline suggests pressures on domestic operations or a shift in focus. Integration risks associated with the Adcock Ingram acquisition also warrant attention.
  • The Forward View: The Board's in-principle approval to evaluate the demerger of the Agro Chemicals business indicates a strategic realignment to unlock value. The incorporation of a new subsidiary in Chile signals expansion into new geographies. The declared interim dividend of ₹1.50 per share signals continued shareholder returns, though the market will likely focus on the underlying operational performance and the rationale behind the sequential revenue shock.

Investors should closely monitor the earnings call scheduled for February 12, 2026, for management's detailed commentary on the QoQ performance drivers and future outlook.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.